SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma

Abstract

Dasatinib may have activity in patients with UPS but is inactive as a single agent in the other sarcoma subtypes included herein. The Bayesian design allowed for the early termination of accrual in 5 subtypes because of lack of drug activity.